SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG is trending as the community rallies around its position as a Bitcoin-native meme coin within the burgeoning Rune ecosystem. Discussions highlight the strong community, fair distribution, and the potential for $DOG to bridge Bitcoin culture with broader markets through its association with $CBLO. The community emphasizes holding through market volatility.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is trending as traders discuss its potential as a privacy-focused alternative to Bitcoin, drawing comparisons to early BTC gains. Community members are pointing to recent investments from figures like the Winklevoss twins, as well as speculation around institutional adoption and regulatory environments favoring privacy coins. Some traders believe ZEC is inversely correlated to Bitcoin and are closely watching technical patterns for potential breakouts.

XPeng, Inc. engages in the design, development, manufacture, and marketing of smart electric vehicles. Its products are environmentally friendly vehicles, namely an SUV (the G3) and a four-door sports sedan (the P7). It also provides a range of services to the clients, including supercharging service, maintenance service, ride-hailing service and vehicle leasing service. The company was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPEV is trending amid discussions about its strategic shift towards AI and robotics, with the unveiling of the 'Iron' humanoid robot driving significant investor interest. The community is actively discussing the potential for XPEV to become a leader in physical AI, expanding beyond its current EV focus, with some comparing it favorably to Tesla. Bullish sentiment is also supported by strong delivery numbers and expansion into new global markets.

Memecoin on Injective taken over by the community.

Nonja

$NONJA is gaining traction as a meme coin on the Injective ($INJ) network, with community members highlighting its strong performance relative to $INJ and its robust, active community.  Discussion revolves around its potential for high returns, especially with the upcoming Injective EVM mainnet and potential ETFs, and the unique qualities of its NFT collections.  The community emphasizes $NONJA's strong fundamentals, burned liquidity, and status as a leading meme coin on the $INJ ecosystem.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

JMIA is trending amid discussions about its recent earnings, investor day, and potential for a short squeeze. Community members are focused on the company's growth prospects in Africa and its path to profitability, with some expressing optimism about long-term targets and potential institutional investment. Bullish sentiment is fueled by perceived undervaluation and the stock's uncorrelated nature to other markets.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

TQQQ is trending amid market volatility and concerns about escalating US-China trade tensions, particularly following Trump's tariff threats. Community discussions revolve around potential support levels, oversold conditions, and whether the dip presents a buying opportunity or signals a deeper correction. Some traders are weighing potential forward splits and earnings from major tech companies like TSLA and NVDA, while others express concerns about an AI bubble and the broader economic impact of geopolitical factors.

Cidara Therapeutics, Inc. engages in developing targeted immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. Its platform, Cloudbreak, enables development of novel drug-Fc conjugates (DFCs) that inhibit specific disease targets while simultaneously engaging the immune system. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Cidara Therapeutics Inc

Cidara Therapeutics is trending due to positive sentiment around a potential acquisition by Merck for $9.2B, which sent the stock soaring. The community is discussing the impact of the deal on options, what happens to shares post-acquisition, and whether a bidding war might further increase the acquisition price. Some investors are also looking at similar companies that may be acquisition targets.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid discussions surrounding the release of Epstein files and their potential implications for Trump. The community is focused on speculation about Trump's connections and any efforts to suppress the release. Political divides are fueling the conversation, with some questioning motives and potential impacts.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshire Hathaway is trending as the community discusses Warren Buffett's firm taking a new multi-billion dollar stake in Google's parent company, Alphabet, signaling a bet on AI and growth stocks. This move has sparked debate, with some seeing it as a smart shift away from Apple, while others question the timing and Buffett's value investing principles. The investment comes amidst market context showing a bullish trend for Berkshire, although the stock is nearing overbought territory.

Tenax Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of products for cardiovascular and pulmonary diseases. The company was founded on May 26, 1967 and is headquartered in Chapel Hill, NC.

Tenax Therapeutics Inc

TENX is trending as investors discuss its strong cash position, low share float, and Phase 3 trials targeting a significant patient population. The community is highlighting the potential for a squeeze, drawing comparisons to other stocks with similar ownership structures and catalysts. Some are noting potential institutional interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Merck reportedly edged out another bidder in late-stage talks that could lead to a deal announcement as soon as Friday.</li><li>Cidara’s CD388 flu antibody, now in phase 3 trials with FDA breakthrough status, has driven significant takeover interest.</li><li>Retail traders debated whether the move signals a full buyout or a milestone-based deal structure.</li></ul><p>Cidara Therapeutics’ shares surged 42% after hours on Thursday following reports that Merck is close to acquiring the biotech in a deal that could be announced as soon as Friday.&nbsp;</p><p>The negotiations reportedly extended late into Thursday as Merck competed with another pharmaceutical group before the seller ultimately favored its offer. The deal is expected to value Cidara above its roughly $3.3 billion market capitalization, though the final price has apparently not been set. Any agreement is likely to include upfront cash and milestone-based payments tied to clinical progress, according to a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/743e1962-3dd1-4785-a20b-4b097e5514ae">report</a> by Financial Times.</p><h2 class="st-heading-2"><strong>Big Pharma Races To Rebuild Pipelines</strong></h2><p>A potential takeover would mark Merck’s latest move to fortify its drug portfolio before Keytruda, its $25 billion-per-year cancer therapy, loses patent protection in 2028. The company agreed in July to buy respiratory drug developer Verona Pharma for $10 billion as part of a broader effort to maintain revenue momentum. The demand for Cidara comes after another big-name auction last week, when&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-loses-metsera-bidding-war-to-pfizer-but-retail-traders-aren-t-losing-faith/cLPcRJWREci">Pfizer narrowly won a race against Novo Nordisk</a> for obesity biotech Metsera in a deal worth as much as $10 billion.</p><h2 class="st-heading-2"><strong>Biotech Sector Heats Up As M&amp;A Wave Accelerates</strong></h2><p>The race for Cidara is unfolding amid a surge in biotechnology dealmaking.&nbsp;<a href="https://stocktwits.com/symbol/XBI">The XBI biotech index</a> has gained over 40% in the past six months as investors bet on a return of acquisitions by big drugmakers looking to add next-generation therapies to their pipelines. The scramble reflects rising urgency across the sector as companies face major revenue losses once key products lose exclusivity.</p><h2 class="st-heading-2"><strong>Cidara’s Lead Flu Antibody Drives Takeover Expectations</strong></h2><p>Cidara’s value surge is tied to its lead program, CD388, a long-acting antibody intended to protect against the two most common strains of influenza. The treatment is being evaluated in phase 3 trials among immunosuppressed patients who cannot receive vaccines, as well as healthy adults over 65. Over 6,000 patients are expected to be enrolled in the studies worldwide by the end of the month. CD388 has been granted an&nbsp;FDA breakthrough designation, which could accelerate regulatory approval. Cidara’s shares have quadrupled since July, driven by strong clinical data and takeover speculation that have fueled investor expectations.</p><h2 class="st-heading-2"><strong>Stocktwits Buzz Highlights Takeover Speculation</strong></h2><p>On Stocktwits, retail sentiment was ‘extremely bullish’ for Cidara and ‘bullish’ for Merck, with both stocks seeing ‘high’ message volume.</p><p>One user reacted to the report by saying, “sounds like $MRK going in for the kill.”</p><p><stembedurl>https://stocktwits.com/JFais/message/636148828</stembedurl></p><p>Another user questioned the structure of the potential deal, writing, “It makes me wonder if it is an actual buyout or an investment in the company for rights to their drug? It mentions the possibility of upfront cash plus milestone payments.... hopefully it is a buyout above the current $150 AH price.”</p><p><stembedurl>https://stocktwits.com/PooPooPewPew/message/636148400</stembedurl></p><p>While&nbsp;<a href="https://stocktwits.com/symbol/CDTX">Cidara’s stock</a> has surged 446% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/MRK">Merk’s stock</a> has risen 18% over the same period.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Cidara Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Cidara Therapeutics Stock Soars 42% After-Hours On Merck Buyout Buzz — Retail Traders Eye A Potential Blowout Premium

Merck reportedly edged out another bidder in late-stage talks that could lead to a deal announcement as soon as Friday.

Equity

Merck Rises 13% in a Week: Should You Buy, Sell or Hold the Stock?

MRK's stock witnesses an upside after Pfizer's pricing deal, but Gardasil's slump and Keytruda's looming LOE keep investors cautious.

Merck Falls 14% YTD: Time to Buy, Sell or Hold the Stock?

Merck stock is down 14% this year as Keytruda-led growth gets offset by Gardasil weakness and looming patent risks, which cloud the outlook.

All You Need to Know About Verona Pharma (VRNA) Rating Upgrade to Buy

Verona Pharma (VRNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Merck's Narrowed 2025 Sales View: What it Means After Q2 Results?

MRK trims its 2025 sales range but lifts the lower end of its EPS outlook. Keytruda, Animal Health and new drugs are expected to drive a second-half rebound.

Merck Stock Down 4% Since Q2 Results: How to Play the Stock

Merck slips following its Q2 results as Gardasil sales slump. However, Keytruda, new launches and a rich pipeline bolster its long-term case.

Volatility-Proof Your Portfolio With VIPS, GDS, FUTU & VRNA Stocks 

Shield your portfolio from market swings with low-beta picks like VIPS, GDS, FUTU and VRNA, each showing strong momentum.

Merck Unveils Cost-Cutting Plan: Can it Create Long-Term Value?

MRK targets $3B in annual savings by 2027 as it cuts jobs and refocuses investment ahead of Keytruda's 2028 patent cliff.

Merck Q2 Earnings Top, Sales Meet Estimates, 2025 View Narrowed

MRK beats second-quarter estimates for EPS while matching the same for sales. The company trims its 2025 outlook.

Merck Q2 Earnings in the Cards: Buy, Sell or Hold Ahead of Results?

MRK is gearing up to report Q2 earnings. While Keytruda drives growth, there are concerns over Gardasil's China sales, generics and pipeline depth. 

Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. It focuses on developing inhaled ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.

Verona Pharma Plc - ADR

Will NVIDIA ($NVDA) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	$0.01	--	--	N/A
Q2 '25	$0.06	-$0.01	-117.67%	MISSED
Q1 '25	-$0.08	-$0.02	73.77%	BEAT
Q4 '24	-$0.03	-$0.05	-81.82%	MISSED
Q3 '24	-$0.07	-$0.07	-2.94%	MISSED

VRNA
Verona Pharma Plc American Depositary

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest VRNA News

VRNAVerona Pharma Plc American Depositary